Rethink unresectable Stage 3 NSCLC

With treatment advances, survival in unresectable Stage 3A‧B‧C NSCLC has improved to the point where achieving a cure may be possible for more of your patients1-3

  • As defined by 5-year overall survival rate for concurrent CRT, which has improved from 15% in 2010 to 32% in 20172-4

Stage 3 NSCLC has a distinct clinical profile from metastatic (Stage 4) disease and has different treatment goals5-7

  • As defined by 5-year overall survival rate for concurrent CRT, which has improved from 15% in 2010 to 32% in 20172-4

Stage 3 NSCLC has a distinct clinical profile from metastatic (Stage 4) disease and has different treatment goals5-7

24% of patients with NSCLC present with Stage 3 disease

~24% of patients with NSCLC present with Stage 3 disease8

 
0

~82% of patients with Stage 3 NSCLC have unresected disease9*

 
 
 

Treatment with curative intent concurrent chemoradiotherapy is given to patients and offers patients additional treatment options in the unresectable Stage 3 NSCLC setting10

 
 
 

Experts Discuss Curative Intent Treatment for Stage 3 NSCLC Patients

Stage 3 lung cancer is a curative intent disease. So we should maximize [the] chance of a cure and minimize toxicity using the tools we discussed today.

–Dr Joe Chang

NSCLC=non-small cell lung cancer; CRT=chemoradiotherapy.

*Unresected disease includes patients with unresectable disease and patients with resectable disease who declined surgical intervention.

The views and opinions expressed in the Art of CRT video series are those of the individual panel members and do not represent the views or opinions of AstraZeneca. These videos contain anecdotal information gathered from a discussion with 8 physicians and nurses based on their opinions/experiences. Recommendations are general and may vary with patients.

References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42. 2. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-2190. 3. Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706-714. 4. Bradley JD, Hu C, Komaki RU, et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys. 2017;99(2S)(suppl):S105. 5. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155. 6. Lung cancer—non-small cell: stages. Cancer.Net website. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/stages. Accessed July 20, 2020. 7. Robinson AG, Young K, Balchin K, Owen T, Ashworth A. Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status? Curr Oncol. 2015;22(6):399-404. 8. EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025. New York, NY: GlobalData; November 2016. 9. Kantar Health CancerMPact. Treatment modality. http://cancermpact.khapps.com. Accessed July 20, 2020. 10. Moore S, Leung B, Wu J, Ho C. Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol. 2019;14(8):1430-1439.